TY - JOUR
TI - Rapid clinical-scale propagation of mesenchymal stem cells using
cultures initiated with immunoselected bone marrow CD105(+) cells
AU - Spiropoulos, Antonia
AU - Theodosaki, Maria
AU - Stefanaki, Kalliopi and
AU - Paterakis, George
AU - Tzetis, Maria
AU - Giannikou, Krinio
AU - Petrakou,
AU - Eftichia
AU - Dimopoulou, Maria N.
AU - Papassotiriou, Ioannis
AU - Roma,
AU - Eleptheria S.
AU - Kanavakis, Emmanuel
AU - Graphakos, Stelios and
AU - Goussetis, Evgenios
JO - Journal of Cellular and Molecular Medicine
PY - 2011
VL - 15
TODO - 9
SP - 1983-1988
PB - Wiley
SN - 1582-1838, 1582-4934
TODO - 10.1111/j.1582-4934.2010.01157.x
TODO - clinical scale expansion; mesenchymal stem cells; CD105(+) cells
TODO - Current clinical protocols used for isolation and purification of
mesenchymal stem cells (MSC) are based on long-term cultures starting
with bone marrow (BM) mononuclear cells. Using a commercially available
immunoselection kit for enrichment of MSC, we investigated whether
culture of enriched BM-CD105(+) cells could provide an adequate number
of pure MSC in a short time for clinical use in the context of graft
versus host disease and graft failure/rejection. We isolated a mean of
5.4 x 10(5) +/- 0.9 x 10(5) CD105(+) cells from 10 small volume (10-25
ml) BM samples achieving an enrichment > 100-fold in MSC. Seeding 2 x
10(3) immunoselected cells/cm(2) we were able to produce 2.5 x 10(8) +/-
0.7 x 10(8) MSC from cultures with autologous serum enriched medium
within 3 weeks. Neither haematopoietic nor endothelial cells were
detectable even in the primary culture cell product. Expanded cells
fulfilled both phenotypic and functional current criteria for MSC; they
were CD29(+), CD90(+), CD73(+), CD105(+), CD45(-); they suppressed
allogeneic T-cell reaction in mixed lymphocyte cultures and retained in
vitro differentiation potential. Moreover, comparative genomic
hybridization analysis revealed chromosomal stability of the cultured
MSC. Our data indicate that adequate numbers of pure MSC suitable for
clinical applications can be generated within a short time using
enriched BM-CD105(+) cells.
ER -